Last edition
News about "telisotuzumab vedotin "
AbbVie Submits BLA to FDA for Teliso-V in Previously Treated Non-Small Cell Lung Cancer
AbbVie has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V).
Telisotuzumab Vedotin | 30/09/2024 | By Aishwarya | 150
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members